Radioiodine Therapy of Thyroid Cancer

  • Ettore Seregni
  • Alice Lorenzoni
  • Laura Fugazzola


Differentiated thyroid cancers are typically iodine-avid and can be effectively treated with radioiodine. In most patients, radioactive iodine therapy (RAI) is done for ablation of residual tissue or with adjuvant intent in case of suspected persistent disease after surgery. Patient with advanced or metastatic disease may also benefit from RAI. In this chapter, we will discuss the current role of 131I-iodide therapy, including patient’s selection and preparation, and the importance of individual response to therapy to guide subsequent patient management.


Radioiodine therapy Thyroid cancer Risk stratification 


  1. 1.
    Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. vol 9. IARC Scientific Publications No. 160. Lyon: IARC; 2007.Google Scholar
  2. 2.
    Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid. 2011;21(2):125–34.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    LiVolsi VA. Papillary neoplasms of the thyroid. Pathologic and prognostic features. Am J Clin Pathol. 1992;97:426–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Ghossein R. Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol. 2010;21:212–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    SEER Stat Fact Sheets: Thyroid Cancer. Surveillance, Epidemiology, and End Results Program. Accessed 12 Mar 2017.
  8. 8.
    Jukkola A, Bloigu R, Ebeling T, et al. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer. 2004;11:571–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Orlov S, Orlov D, Shaytzag M, et al. Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck. 2009;31:782–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Baek SK, Jung KY, Kang SM, et al. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. 2010;20:147–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Vaisman F, Momesso D, Bulzico DA, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol. 2012;77:132–8.CrossRefGoogle Scholar
  13. 13.
    American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mclver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefGoogle Scholar
  14. 14.
    Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European thyroid cancer taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.CrossRefPubMedGoogle Scholar
  15. 15.
    Edmonds CJ, Hayes S, Kermode JC, et al. Measurement of serum TSH and thyroid hormones in the management and treatment of thyroid carcinoma with radioiodine. Br J Radiol. 1977;50:799–807.CrossRefPubMedGoogle Scholar
  16. 16.
    Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009;94(11):4171–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Piccardo A, Arecco F, Puntoni M, et al. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med. 2013;38:18–2.CrossRefPubMedGoogle Scholar
  20. 20.
    Maxon HR 3rd, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med. 1992;33:1132–6.PubMedGoogle Scholar
  21. 21.
    Maenpaa HO, Heikkonen J, Vaalavirta L, et al. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One. 2008;2(3):e1885.CrossRefGoogle Scholar
  22. 22.
    Castagna MG, Cevenini G, Theodoropoulou A, et al. Postsurgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. 2013;169:23–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Verburg FA, Mader U, Reiners C, et al. Long term survival in DTC is worse after low-activity initial post-surgical I-131 therapy in both high and low risk patients. J Clin Endocrinol Metab. 2014;99:4487–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Fatourechi V, Hay ID, Mullan BP, et al. Are post-therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2009;10:573–7.CrossRefGoogle Scholar
  25. 25.
    Souza Rosario PW, Barroso AL, Rezende LL, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med. 2004;29:795–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:1381–91.CrossRefPubMedGoogle Scholar
  27. 27.
    Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F, et al. Efficacy of 131 dosimetric versus empiric prescribed activity of I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96(10):3217–25.CrossRefPubMedGoogle Scholar
  28. 28.
    Baudin E, Schlumberger M. Metastasis of differentiated cancers of the thyroid. Ann Endocrinol (Paris). 1997;58:326–9.Google Scholar
  29. 29.
    Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22:884–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19:451–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ettore Seregni
    • 1
  • Alice Lorenzoni
    • 1
  • Laura Fugazzola
    • 2
    • 3
  1. 1.Nuclear MedicineFondazione IRCCS Istituto Nazionale TumoriMilanItaly
  2. 2.Division of Endocrine and Metabolic DiseasesIRCCS Istituto Auxologico ItalianoMilanItaly
  3. 3.Department of Pathophysiology and TransplantationUniversity of MilanMilanItaly

Personalised recommendations